Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 7/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14043165 | 0.93 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1MAP3K12 | |
| SCHEMBL14418924 | 0.92 | GSK3B (0.55) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13119223 | 0.91 | GSK3B (0.65) | GSK3BCDK2CCNE1 | |
| SCHEMBL14418839 | 0.89 | GSK3B (0.50) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL14418830 | 0.89 | GSK3B (0.51) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL14301230 | 0.88 | GSK3B (0.53) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL14545902 | 0.87 | GSK3B (0.56) | GSK3BCHEK1CDK2CCNE1 | |
| SCHEMBL13304610 | 0.86 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL13305284 | 0.86 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1VNN1 | |
| SCHEMBL13304611 | 0.86 | GSK3B (0.59) | GSK3BCHEK1CDK2CCNE1VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2194058-A1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | SCHERING CORPORATION (US) | 2010-06-09 | — | — | EP | disclosed |